FindTrial
Sign In

A multicenter, retrospective study on clinical profile, treatment, and outcome of LCH in India

A multicentre, retrospective study on demography, presentation, treatment, and outcome of Langerhans cell histiocytosis in India(LCH-INDIA) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/12/077952
Enrollment
150
Registered
2024-12-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R00-R99- Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

India Pediatric Hematology Oncology Group INPHOG
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children Up to 18 years of age diagnosed with biopsy proven LCH except for isolated CNC LCH where biopsy is not feasible. 2. Children receiving primary treatment in the participating Centre

Exclusion criteria

Exclusion criteria: Records not available

Design outcomes

Primary

MeasureTime frame
1. To obtain data on demography, presentataion (Clinical, imaging, laboratorty) in childhood LCH 2. To obtain data on treatment provided for childhood LCH 3. To analyse overall survival and event free survival in childhood LCHTimepoint: 10 years—

Secondary

MeasureTime frame
1. To obtain data on incidence of relapses/reactivations and second line treatment offered 2. To obtain data on outcome following reactivation of LCH in IndiaTimepoint: 10 years—

Countries

India

Contacts

Public ContactDr Ramya Uppuluri

Apollo Cancer centre

drramya_u@apollohospitals.com8939710906

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026